Media headlines about NuVasive (NASDAQ:NUVA) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 46.8446180547279 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Stock at 52-Week High – NuVasive, Inc. (NUVA) – Should You Buy? (thestocksnews.com)
- Research Shows NuVasive Porous PEEK Structure Maintains High Porosity After Impaction (finance.yahoo.com)
- Why Is NuVasive (NUVA) Up 4.6% Since Its Last Earnings Report? (finance.yahoo.com)
- Global Spine Biologics Market Share 2018 Wright Medical Technology, Orthofix International, Nuvasive and Stryker … (journalhealthcare.com)
- NuVasive, Inc. (NUVA) stock jumped 0.61% versus to SMA-20 (thestocksnews.com)
Several brokerages have weighed in on NUVA. BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $70.00 target price (down from $71.00) on shares of NuVasive in a research report on Tuesday, February 27th. Canaccord Genuity dropped their target price on shares of NuVasive from $81.00 to $73.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cowen set a $62.00 target price on shares of NuVasive and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Barclays reiterated a “buy” rating and set a $62.00 price objective (down from $66.00) on shares of NuVasive in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company. NuVasive currently has a consensus rating of “Buy” and a consensus target price of $67.27.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Monday, February 26th. The medical device company reported $0.56 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.56. NuVasive had a net margin of 8.06% and a return on equity of 13.40%. The company had revenue of $271.70 million for the quarter, compared to analyst estimates of $272.11 million. During the same period in the prior year, the firm posted $0.53 EPS. The company’s quarterly revenue was up .2% on a year-over-year basis. sell-side analysts anticipate that NuVasive will post 2.46 earnings per share for the current year.
In related news, CEO Gregory T. Lucier bought 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average price of $50.30 per share, for a total transaction of $301,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is owned by insiders.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.